Silexion Therapeutics Receives Approval from Germany's BfArM to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic CancerUnusual Whales·Jun 25 at 01:21 PMSLXN+11.45%
Silexion Therapeutics Receives Approval from Germany's BfArM to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer | SLXN Stock NewsStockTitan·Jun 22 at 11:40 PMSLXN+11.45%
Silexion Therapeutics presentation highlights SIL204 siRNA program targeting KRAS-driven pancreatic cancerPUBT·Jun 22 at 07:38 AMSLXN+11.45%
Silexion Therapeutics to Attend BIO International Convention 2026 | SLXN Stock NewsStockTitan·Jun 16 at 07:30 AMSLXN+11.45%
Silexion Therapeutics Announces 1-for-10 Reverse Share SplitUnusual Whales·Jun 4 at 06:57 PMSLXN+11.45%
Silexion Therapeutics shares are trading lower after the company announced a 1-for-10 reverse share split.benzinga_article·May 26 at 08:03 AMSLXN+11.45%IBB+0.10%
SLXN On Track, IMVT Hits New High, CTEV Eyes Blockbuster Revenue, Big Day Ahead For BDTXrttnews·May 20 at 09:20 PMHCWB+6.00%SLXN+11.45%
12 Health Care Stocks Moving In Wednesday's Intraday Sessionbenzinga_article·May 20 at 12:05 PMSLXN+11.45%HCWB+6.00%
Nasdaq Gains 100 Points; Target Earnings Top Viewsbenzinga_article·May 20 at 08:46 AM.IXIC-0.18%TGT+2.60%
Silexion Therapeutics Announces Warrant Inducement Financing AgreementTip Ranks·May 15 at 05:44 PMSLXN+11.45%IHE+0.51%
Silexion Therapeutics Corp 1Q 2026: Net loss $2.7M, EPS ($0.85) — 10-Q SummaryTradingView·May 15 at 04:31 PMSLXN+11.45%IXJ+0.61%
